HAYA Therapeutics
1066 Epalinges, VD, Switzerland
About HAYA Therapeutics
At HAYA Therapeutics, we are revolutionizing RNA-guided genome-targeting therapies to treat fibrosis, heart failure, and other serious chronic diseases associated with aging. Our innovative platform leverages long non-coding RNAs (lncRNAs) - key regulators within the “dark matter” of the genome - to develop first-in-class, highly specific therapies that reprogram disease-driving cell states into a healthy and resilient state, tackling disease at its roots.
Following the successful close of our Series A financing, HAYA is well-positioned to advance our pipeline and execute on key scientific and operational milestones, including the advancement of HAYA’s lead program, HTX-001, toward the clinic for the treatment of non-obstructive hypertrophic cardiomyopathy (nHCM).
In recognition of our scientific innovation and potential global impact, we have been named one of the 100 early-stage companies selected for the World Economic Forum’s 2025 Technology...
